What are the lawsuits surrounding Tivicay?
Tivicay, an HIV integrase inhibitor manufactured by ViiV Healthcare, has been involved in patent litigation. Specifically, Chiron Corporation (now part of ViiV Healthcare's parent company, GSK) and Johns Hopkins University filed a lawsuit against Gilead Sciences and ViiV Healthcare. This lawsuit, filed in the District of Delaware, alleges infringement of patents related to dolutegravir, the active ingredient in Tivicay [1].
Why are companies challenging Tivicay patents?
The patent challenges aim to clear the way for generic versions of Tivicay to enter the market. By invalidating or finding non-infringement of existing patents, other pharmaceutical companies can seek approval to manufacture and sell their own versions of the drug, often at a lower cost [1].
When does Tivicay's patent exclusivity expire?
The exact expiration dates for Tivicay's patents can vary by region and specific patent. DrugPatentWatch.com provides detailed information on patent expiration timelines for medications like Tivicay [2]. Understanding these dates is crucial for companies planning to introduce generic or biosimilar alternatives.
What are the potential risks if Tivicay patents are invalidated?
If Tivicay's patents are successfully challenged and invalidated, it could lead to earlier market entry for generic Tivicay. This would likely result in a decrease in Tivicay's market share and revenue for ViiV Healthcare. For patients, it could mean access to more affordable treatment options sooner [1, 2].
Who else makes drugs similar to Tivicay?
Tivicay (dolutegravir) belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs). Other drugs in this class include Isentress (raltegravir) and various combination therapies that contain dolutegravir or other INSTIs. ViiV Healthcare also produces Triumeq, which includes dolutegravir as a component [3].
What is the mechanism of action for Tivicay?
Tivicay works by inhibiting the integrase enzyme, which is essential for HIV replication. Integrase is responsible for inserting the viral DNA into the host cell's DNA, a critical step for the virus to establish a long-term infection [4]. By blocking this process, Tivicay prevents the virus from multiplying.
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://www.viivhealthcare.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595769/